Immunovant, Inc.
IMVT · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2,590 | $4,365 | $1,909 | $604 |
| - Cash | $714 | $635 | $377 | $494 |
| + Debt | $0 | $0 | $1 | $2 |
| Enterprise Value | $1,877 | $3,730 | $1,534 | $113 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$438 | -$270 | -$208 | -$156 |
| % Margin | – | – | – | – |
| Net Income | -$414 | -$259 | -$211 | -$157 |
| % Margin | – | – | – | – |
| EPS Diluted | -2.73 | -1.88 | -1.71 | -1.43 |
| % Growth | -45.2% | -9.9% | -19.6% | – |
| Operating Cash Flow | -$376 | -$214 | -$188 | -$106 |
| Capital Expenditures | -$1 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$377 | -$215 | -$188 | -$106 |